Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. [electronic resource]
Producer: 20150408Description: 1111-27 p. digitalISSN:- 1865-8652
- Age Factors
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Cohort Studies
- Cost-Benefit Analysis
- Databases, Factual
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Health Care Costs
- Humans
- Intravitreal Injections
- Linear Models
- Male
- Middle Aged
- Multivariate Analysis
- Poisson Distribution
- Ranibizumab
- Receptors, Vascular Endothelial Growth Factor -- administration & dosage
- Recombinant Fusion Proteins -- administration & dosage
- Retrospective Studies
- Risk Assessment
- Severity of Illness Index
- Sex Factors
- Time Factors
- Treatment Outcome
- United States
- Vascular Endothelial Growth Factor A -- administration & dosage
- Wet Macular Degeneration -- diagnosis
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.